← Signals · Healthcare · TSX
$FRX
Fennec Pharmaceuticals Inc.
Signal as of N/A  ·  90-day rolling window  ·  Biotechnology & Life Sciences
Confluence Score
—
out of 100  ·  Full breakdown →
Score delayed 7 days on Free  ·  See today's score — Analyst →
Signals scoring 20–39 have historically hit 47% of the time (avg +6.8% over 90 days, 105 backtested signals). Methodology →
🔒 Risk monitoring — insider-selling & reversal warnings (Analyst)
5 open-market buys  ·  5 unique buyers  ·  — total Lobbying: 0 regs  ·  Contracts: 0 wins
📅 Buying into earnings — Aug 13 (35d)
Confluence Score
—
Unlock breakdown →
Insider Activity (90d)
5
5 buyers  ·  —  ·  open-market only
Current Price
$14.50
CAD  ·  5-min cache
Market Cap
$506M
CAD  ·  TMX
Lobbying & Contracts
None
0 regs  ·  0 contracts
Healthcare on Form55: 43% hit rate · -5.4% alpha vs XIU.TO · 21 closed signals Track Record →
★
Signal Analyst
The Confluence Score and insider trade feed above are free. Signal Analyst adds the full component breakdown, lobbying registrations, and contract wins — plus alerts when this company's signal moves, so you don't have to keep checking back.
Monitor — CAD $29/mo
Price Chart
12 months daily  ·  TSX:FRX
Insider Transactions
90-day window  ·  9 filings
Date Insider Role Nature Dir. Shares Buy Price Return Value
Jul 01, 2026 Evans, Terry — Open Market Buy 168 — — —
Jul 01, 2026 Sayad, Pierre — Open Market Buy 168 — — —
Jul 01, 2026 Andrade, Robert Christopher — Open Market Buy 1,703 — — —
Jul 01, 2026 Hackman, Jeffrey — Open Market Buy 1,159 — — —
Jul 01, 2026 Cioffi, Christiana — Open Market Buy 156 — — —
Jun 10, 2026 Jodi, Cook — Comp. Grant Buy 20,000 $8.70 +66.7%  · 29d $174K
Jun 10, 2026 Brughera, Marco — Comp. Grant Buy 20,000 $8.70 +66.7%  · 29d $174K
Jun 10, 2026 Rallis, Chris Anigeron — Comp. Grant Buy 20,000 $8.70 +66.7%  · 29d $174K
Jun 10, 2026 Islam, Khalid — Comp. Grant Buy 25,000 $8.70 +66.7%  · 29d $218K
Score uses open-market buys only  ·  5 open-market  ·  4 plan / compensation shown but not scored  ·  Return is unrealized, to today's price; a “· Nd” mark means the 90-day window is still open (N of 90 days) — too early to judge.
Score Breakdown
Signal Analyst  ·  $29/mo
Component Points Max Detail Weight
Conviction (unique buyers)  ✓ FREE PREVIEW 20 30 5 unique buyers
Buy/sell ratio 20 100% buys (5B / 0S)
Dollar value 25 No open-market buys
Lobbying activity 15 None
Contract wins 10 None
Insider track record 10 No track record data
Private placements 8 None
Confluence bonus 10 None
Cluster timing (velocity) 10 No coordinated buying cluster detected
Buy/sell reversal pattern 8 No buy/sell reversal pattern
Total 0 100
Unlock Component Detail — CAD $29/mo
Buying Insiders
Open-market · 90 days · 5 unique buyers
Insider Credibility Hit Rate Avg 90d Return Trades (eval'd) Buy Value (90d) Last Buy
Evans, Terry — — — — — Jul 01, 2026
Sayad, Pierre — — — — — Jul 01, 2026
Andrade, Robert Christopher — — — — — Jul 01, 2026
Hackman, Jeffrey — — — — — Jul 01, 2026
Cioffi, Christiana — — — — — Jul 01, 2026
Credibility score: historical hit rate × avg 90d return × sample size. View full insider leaderboard →
Lobbying Registrations
OCL active  ·  none found
No active OCL lobbying registrations in the last 90 days. Analyst plan →
Government Contract Wins
90-day window  ·  none found
No government contract wins in the last 90 days. Analyst plan →
Private Placements
12 months  ·  Signal Analyst  ·  $29/mo
Private placement history, deal size, and lock-up expiry tracking. Analyst plan →
Indigenous Consultation
no records on file

No Indigenous consultation records on file for FRX.

SEDAR+ Filings
official filing registry
Form55 monitors SEDAR+ filing alerts and newswire announcements for Technical Reports and material changes. Search SEDAR+ →
Short Interest
CIRO  ·  Jun 30, 2026
Shares short
24,671
Net change
+1,263 (+5.4%)
History
Jun 30: 24,671
Jun 15: 23,408
May 31: 24,099
May 15: 24,604
Apr 30: 27,523
Apr 15: 29,067
Aggregate short position from CIRO's Consolidated Short Position Report (published twice monthly).
Form55 provides data and analysis for informational purposes only. Nothing on this site constitutes investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results.